Literature DB >> 25663093

Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe.

A J Turley1, B Gathmann, C Bangs, M Bradbury, S Seneviratne, L I Gonzalez-Granado, S Hackett, N Kutukculer, H Alachkar, S Hambleton, H Ritterbusch, P Kralickova, L Marodi, M G Seidel, G Dueckers, J Roesler, A Huissoon, H Baxendale, J Litzman, P D Arkwright.   

Abstract

INTRODUCTION: Complement immunodeficiencies (excluding hereditary angioedema and mannose binding lectin deficiency) are rare. Published literature consists largely of case reports and small series. We collated data from 18 cities across Europe to provide an overview of primarily homozygous, rather than partial genotypes and their impact and management.
METHODS: Patients were recruited through the ESID registry. Clinical and laboratory information was collected onto standardized forms and analyzed using SPSS software.
RESULTS: Seventy-seven patients aged 1 to 68 years were identified. 44 % presented in their first decade of life. 29 % had C2 deficiency, defects in 11 other complement factors were found. 50 (65 %) had serious invasive infections. 61 % of Neisseria meningitidis infections occurred in patients with terminal pathway defects, while 74 % of Streptococcus pneumoniae infections occurred in patients with classical pathway defects (p < 0.001). Physicians in the UK were more likely to prescribe antibiotic prophylaxis than colleagues on the Continent for patients with classical pathway defects. After diagnosis, 16 % of patients suffered serious bacterial infections. Age of the patient and use of prophylactic antibiotics were not associated with subsequent infection risk. Inflammatory/autoimmune diseases were not seen in patients with terminal pathway, but in one third of patients classical and alternative pathway defects.
CONCLUSION: The clinical phenotypes of specific complement immunodeficiencies vary considerably both in terms of the predominant bacterial pathogen, and the risk and type of auto-inflammatory disease. Appreciation of these phenotypic differences should help both immunologists and other specialists in their diagnosis and management of these rare and complex patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25663093     DOI: 10.1007/s10875-015-0137-5

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  40 in total

Review 1.  Membranoproliferative glomerulonephritis--a new look at an old entity.

Authors:  Sanjeev Sethi; Fernando C Fervenza
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

2.  Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.

Authors:  Asghar Aghamohammadi; Payam Mohammadinejad; Hassan Abolhassani; Babak Mirminachi; Masoud Movahedi; Mohammad Gharagozlou; Nima Parvaneh; Vaheid Zeiaee; Bahram Mirsaeed-Ghazi; Zahra Chavoushzadeh; Alireza Mahdaviani; Mahboubeh Mansouri; Sedigheh Yousefzadegan; Bahareh Sharifi; Fariborz Zandieh; Ehsan Hedayat; Ali Nadjafi; Roya Sherkat; Behzad Shakerian; Mahnaz Sadeghi-Shabestari; Reza Farid Hosseini; Farahzad Jabbari-Azad; Hamid Ahanchian; Fatemeh Behmanesh; Mohammadreza Zandkarimi; Afshin Shirkani; Taher Cheraghi; Abbas Fayezi; Iraj Mohammadzadeh; Reza Amin; Soheila Aleyasin; Mojgan Moghtaderi; Javad Ghaffari; Saba Arshi; Naser Javahertrash; Mohammad Nabavi; Mohammad Hassan Bemanian; Alireza Shafiei; Najmedin Kalantari; Akefeh Ahmadiafshar; Hossein Ali Khazaei; Lida Atarod; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

3.  A familial deficiency of the phagocytosis-enhancing activity of serum related to a dysfunction of the fifth component of complement (C5).

Authors:  M E Miller; U R Nilsson
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

Review 4.  Immunology of age-related macular degeneration.

Authors:  Jayakrishna Ambati; John P Atkinson; Bradley D Gelfand
Journal:  Nat Rev Immunol       Date:  2013-06       Impact factor: 53.106

5.  Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations.

Authors:  Lora Boteva; David L Morris; Josefina Cortés-Hernández; Javier Martin; Timothy J Vyse; Michelle M A Fernando
Journal:  Am J Hum Genet       Date:  2012-03-01       Impact factor: 11.025

Review 6.  Mannose-binding lectin in innate immunity: past, present and future.

Authors:  R M Dommett; N Klein; M W Turner
Journal:  Tissue Antigens       Date:  2006-09

7.  Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.

Authors:  Peter Hillmen; Petra Muus; Alexander Röth; Modupe O Elebute; Antonio M Risitano; Hubert Schrezenmeier; Jeffrey Szer; Paul Browne; Jaroslaw P Maciejewski; Jörg Schubert; Alvaro Urbano-Ispizua; Carlos de Castro; Gérard Socié; Robert A Brodsky
Journal:  Br J Haematol       Date:  2013-04-25       Impact factor: 6.998

Review 8.  Meningococcal disease and the complement system.

Authors:  Lisa A Lewis; Sanjay Ram
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

Review 9.  Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

Authors:  Edwin K S Wong; Tim H J Goodship; David Kavanagh
Journal:  Mol Immunol       Date:  2013-06-28       Impact factor: 4.174

Review 10.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Tim H Goodship; Anna Richards
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

View more
  20 in total

1.  Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.

Authors:  Ciro Romano; Andrea Del Mastro; Ausilia Sellitto; Eleonora Solaro; Sergio Esposito; Giovanna Cuomo
Journal:  Clin Rheumatol       Date:  2018-01-23       Impact factor: 2.980

Review 2.  The yin and the yang of early classical pathway complement disorders.

Authors:  Kathleen E Sullivan
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

3.  Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract.

Authors:  Bruno Corsini; Roberto Díez-Martínez; Leire Aguinagalde; Fernando González-Camacho; Esther García-Fernández; Patricia Letrado; Pedro García; Jose Yuste
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

4.  Infections Revealing Complement Deficiency in Adults: A French Nationwide Study Enrolling 41 Patients.

Authors:  A Audemard-Verger; E Descloux; D Ponard; A Deroux; B Fantin; C Fieschi; M John; A Bouldouyre; L Karkowsi; G Moulis; H Auvinet; F Valla; C Lechiche; B Davido; M Martinot; C Biron; F Lucht; N Asseray; A Froissart; R Buzelé; A Perlat; D Boutboul; V Fremeaux-Bacchi; S Isnard; B Bienvenu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

5.  Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?

Authors:  Naveen Raj; Barry Waters
Journal:  Case Rep Rheumatol       Date:  2016-12-15

6.  Recurrent invasive meningococcal infections - quantifying the risk, Germany, 2002 to 2018.

Authors:  Manuel Krone; Thiên-Trí Lâm; Heike Claus; Ulrich Vogel
Journal:  Euro Surveill       Date:  2020-06

7.  Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosis.

Authors:  Rosa Maria Dellepiane; Laura Dell'Era; Paola Pavesi; Paolo Macor; Mara Giordano; Luca De Maso; Maria Cristina Pietrogrande; Massimo Cugno
Journal:  Orphanet J Rare Dis       Date:  2016-05-17       Impact factor: 4.123

Review 8.  Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway.

Authors:  Ana Catarina Lunz Macedo; Lourdes Isaac
Journal:  Front Immunol       Date:  2016-02-24       Impact factor: 7.561

9.  Functional Complement Analysis Can Predict Genetic Testing Results and Long-Term Outcome in Patients With Complement Deficiencies.

Authors:  Štefan Blazina; Maruša Debeljak; Mitja Košnik; Saša Simčič; Sanja Stopinšek; Gašper Markelj; Nataša Toplak; Peter Kopač; Breda Zakotnik; Marko Pokorn; Tadej Avčin
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

10.  Reg4 and complement factor D prevent the overgrowth of E. coli in the mouse gut.

Authors:  Houbao Qi; Jianmei Wei; Yunhuan Gao; Yazheng Yang; Yuanyuan Li; Hua Zhu; Lei Su; Xiaomin Su; Yuan Zhang; Rongcun Yang
Journal:  Commun Biol       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.